UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000005219 |
|---|---|
| Receipt number | R000006190 |
| Scientific Title | Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes |
| Date of disclosure of the study information | 2011/03/08 |
| Last modified on | 2018/09/18 15:50:48 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2011/03/08 15:39:56 | ||
| 2 | Update | 2011/08/01 09:58:32 | Key inclusion criteria |
|
| 3 | Update | 2012/08/30 18:31:53 | Key inclusion criteria Key inclusion criteria Key exclusion criteria |
|
| 4 | Update | 2012/08/30 18:33:00 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
| 5 | Update | 2014/02/12 13:55:21 | Target sample size |
|
| 6 | Update | 2015/01/07 13:10:27 | Recruitment status |
|
| 7 | Update | 2017/01/10 10:02:00 | Recruitment status |
|
| 8 | Update | 2018/09/18 15:36:08 | Recruitment status Publication of results URL related to results and publications |
|
| 9 | Update | 2018/09/18 15:50:48 | URL related to results and publications |
